NASDAQ:SMMTSUMMIT THERAPEU/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SUMMIT THERAPEU/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.04 +0.03 (+0.75 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$3.94Now: $4.04▼$4.0550-Day Range$2.57MA: $3.58▼$4.4052-Week Range$1.13Now: $4.04▼$5.49Volume16,510 shsAverage Volume147,529 shsMarket Capitalization$129.68 millionP/E RatioN/ADividend YieldN/ABeta0.59 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingSUMMIT THERAPEU/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, SUMMIT THERAPEU/S has a potential downside of 1.0% from its current price of $4.04.Amount of Analyst CoverageSUMMIT THERAPEU/S has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesSUMMIT THERAPEU/S has received 280 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSUMMIT THERAPEU/S has received 342 “underperform” votes. (Add your “underperform” vote.)Community SentimentSUMMIT THERAPEU/S has received 54.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote “Outperform” if you believe SMMT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSUMMIT THERAPEU/S does not currently pay a dividend.Dividend GrowthSUMMIT THERAPEU/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SUMMIT THERAPEU/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 26.23% of the stock of SUMMIT THERAPEU/S is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SUMMIT THERAPEU/S are expected to grow in the coming year, from ($0.74) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SUMMIT THERAPEU/S is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SUMMIT THERAPEU/S is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSUMMIT THERAPEU/S has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.01 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT Previous Symbol CUSIPN/A CIK1599298 Webwww.summitplc.com Phone44-12-3544-3939Debt Debt-to-Equity Ratio0.02 Current Ratio3.26 Quick Ratio3.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$56.50 million Price / Sales2.30 Cash Flow$1.13 per share Price / Cash Flow3.57 Book Value$4.08 per share Price / Book0.99Profitability EPS (Most Recent Fiscal Year)$0.84 Net Income$9.99 million Net Margins-2,107.69% Return on Equity-59.95% Return on Assets-42.26%Miscellaneous Employees61 Outstanding Shares32,100,000Market Cap$129.68 million Next Earnings Date6/10/2020 (Estimated) OptionableOptionable NASDAQ:SMMT Rates by TradingView Receive SMMT News and Ratings via Email Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions How has SUMMIT THERAPEU/S's stock been impacted by COVID-19 (Coronavirus)? SUMMIT THERAPEU/S's stock was trading at $1.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SMMT stock has increased by 113.8% and is now trading at $4.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of SUMMIT THERAPEU/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SUMMIT THERAPEU/S. When is SUMMIT THERAPEU/S's next earnings date? SUMMIT THERAPEU/S is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for SUMMIT THERAPEU/S. How were SUMMIT THERAPEU/S's earnings last quarter? SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.13. The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $4.44 million. SUMMIT THERAPEU/S had a negative return on equity of 59.95% and a negative net margin of 2,107.69%. View SUMMIT THERAPEU/S's earnings history. What price target have analysts set for SMMT? 1 brokers have issued twelve-month price targets for SUMMIT THERAPEU/S's stock. Their forecasts range from $4.00 to $4.00. On average, they expect SUMMIT THERAPEU/S's stock price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 1.0%. View analysts' price targets for SUMMIT THERAPEU/S. Has SUMMIT THERAPEU/S been receiving favorable news coverage? Media stories about SMMT stock have been trending negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SUMMIT THERAPEU/S earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutSUMMIT THERAPEU/S. Who are some of SUMMIT THERAPEU/S's key competitors? Some companies that are related to SUMMIT THERAPEU/S include NewLink Genetics (NLNK), Urogen Pharma (URGN), Organogenesis (ORGO), Emisphere Technologies (EMIS), BioDelivery Sciences International (BDSI), Trillium Therapeutics (TRIL), BioSpecifics Technologies (BSTC), DURECT (DRRX), Neoleukin Therapeutics (NLTX), Beyondspring (BYSI), VBI Vaccines (VBIV), Protagonist Therapeutics (PTGX), Satsuma Pharmaceuticals (STSA), Flexion Therapeutics (FLXN) and Fulcrum Therapeutics (FULC). View all competitors. What other stocks do shareholders of SUMMIT THERAPEU/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other SUMMIT THERAPEU/S investors own include Energy Transfer LP Unit (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Catabasis Pharmaceuticals (CATB), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Dynavax Technologies (DVAX), Ford Motor (F) and Martin Midstream Partners (MMLP). Who are SUMMIT THERAPEU/S's key executives? SUMMIT THERAPEU/S's management team includes the following people: Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)Ms. Michelle Avery, Director of Investor Relations When did SUMMIT THERAPEU/S IPO? (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. What is SUMMIT THERAPEU/S's stock symbol? SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT." Who are SUMMIT THERAPEU/S's major shareholders? SUMMIT THERAPEU/S's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (0.61%), Acadian Asset Management LLC (0.28%) and Inscription Capital LLC (0.05%). Which major investors are selling SUMMIT THERAPEU/S stock? SMMT stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Morgan Stanley. Which major investors are buying SUMMIT THERAPEU/S stock? SMMT stock was bought by a variety of institutional investors in the last quarter, including Inscription Capital LLC. How do I buy shares of SUMMIT THERAPEU/S? Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is SUMMIT THERAPEU/S's stock price today? One share of SMMT stock can currently be purchased for approximately $4.04. How big of a company is SUMMIT THERAPEU/S? SUMMIT THERAPEU/S has a market capitalization of $129.68 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe. What is SUMMIT THERAPEU/S's official website? The official website for SUMMIT THERAPEU/S is www.summitplc.com. How can I contact SUMMIT THERAPEU/S? SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
